Refine by
Disease Early Articles & Analysis
124 news found
In diagnostics, the use of antigen rapid test kits and in vitro diagnostic hematology is accelerating early disease detection, improving treatment outcomes. Meanwhile, supragingival scaling techniques are advancing dental care, while central medical gas systems are ensuring optimal clinical environments. ...
Milan, Italy, September 3, 2024 — Tethis S.p.A., a pioneer in the development of a standardized liquid biopsy platform, announces a collaboration with Weill Cornell Medicine to test Tethis’ instruments for monitoring the response to curative treatment in patients with early-stage breast cancer. The scientists will collect blood from the patients and will measure the ...
Tempus, a leader in artificial intelligence and precision medicine, today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM test and the xM (NeXT Personal® Dx) test by Personalis. The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help detect residual ...
ByTempus
Pancreatic cancer (PC) is a severe disease that is difficult to diagnose in the early stages due to its complex and hidden nature. ...
From data to diagnostics and imaging, drug development and discovery, early intervention and predictive analytics, remote patient monitoring and robotics, AI is revolutionizing healthcare as we know it. ...
In the face of emerging infectious diseases, early detection and swift response are critical to preventing widespread outbreaks. ...
Compounding that, nearly a third of patients who are newly diagnosed will have metastatic disease. We are therefore delighted that patients in China will now have a new treatment option for metastatic hormone-sensitive prostate cancer that delays disease progression, extends survival and maintains quality of life”, said Christine Roth, Member of the ...
ByBayer AG
” Lifespin is working to build new precision medicine tools based on quantitative metabolic profiles and proprietary algorithms to assist in the early detection of diseases and monitoring the efficacy of health treatments. To facilitate these services, the company has established one of the largest and most comprehensive databases of metabolic health ...
Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at asymptomatic precursor stages Menarini Silicon Biosystems, a pioneer of liquid biopsy ...
Food and Drug Administration (FDA) has approved ORSERDU for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. ...
The companies will jointly develop the compounds for the multiple system atrophy (MSA) and Parkinson’s disease (PD) indications based on early-stage clinical studies, and consider exploring additional indications based on clinical outcomes. ...
Julia Camps Herrero, Corporate Chief of Breast Health, Ribera Salud Hospitals Spain. “Early detection of cancer can save lives. Imaging options such as contrast-enhanced mammography can help improve diagnostic accuracy, potentially identifying cancers that otherwise might have been ...
ByBayer AG
OCT fundus cameras like the Topcon Maestro2 allow us to see a greater detailed image of the eye to find pathology and manage diseases early.” By cross-cutting the retina in a manner similar to an MRI machine, OCT’s high-resolution imaging creates a 3D map of a patient’s eye, enabling doctors to diagnose eye diseases in a single ...
Osteoporosis is a disorder that causes the bone density to reduce with time, making bones so weak they get fractured even with a light fall. Regular testing has many benefits as it is tracked by HEDIS (Healthcare Effectiveness Data and Information) to ensure early detection among women to manage their condition properly. Read on to know ...
(NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Conference being held January 10-13, 2022. ...
Meanwhile, a large number of potential candidate peptides targeting the metabolic, cardiovascular, central and peripheral nervous systems, as well as endocrine, immune, hematological, allergic, and other malignant diseases, are in early-stage research or clinical trials. The structural complexity and heterogeneity of Fc fusion proteins require comprehensive ...
About Lumos Pharma Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, ...
About Lumos Pharma Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, ...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner Roche (SIX: RO, ROG; OTCQX: RHHBY) provided an update on the GRADUATE I and II studies evaluating gantenerumab in people with early Alzheimer’s disease (AD). The studies did not meet their primary endpoint of slowing clinical decline. ...
“Patients with advanced stages of cutaneous T-cell lymphomas often have few treatment options left when their disease progresses, and experience lower quality of life and poor life expectancy. ...